FindTrial
Sign In

Mechanism of miRNA-144 regulating GRß expression and promoting glucocorticoid resistance in the treatment of acute respiratory distress syndrome

Mechanism of miRNA-144 regulating GRß expression and promoting glucocorticoid resistance in the treatment of acute respiratory distress syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110651
Enrollment
Unknown
Registered
2025-10-17
Start date
2025-11-01
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Interventions

ARDS group receiving glucocorticoid therapy:Administer 100ml of physiological saline and 80mg of methylprednisolone sodium succinate intravenously once daily for 5 days for treatment.

Sponsors

Shengli Oilfield Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Adult inpatients aged >=18 years; 2. Patients meeting the criteria for moderate to severe ARDS according to the Berlin definition; 3. Signed informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Uncontrolled diabetes and hypertension; 3. Contraindications to glucocorticoid use; 4. Lack of active treatment willingness.

Design outcomes

Primary

MeasureTime frame
miRNA-144;GRa mRNA;GRß mRNA;NF-?B mRNA;Improvement status;—

Secondary

MeasureTime frame
Plasma inflammatory markers (e.g., white blood cell count, neutrophil percentage, C-reactive protein, procalcitonin, etc.);Oxygenation index;—

Countries

China

Contacts

Public ContactHong Shukun

Shengli Oilfield Central Hospital

hongshukun@126.com+86 546 877 9023

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026